{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T11:55:06Z","timestamp":1774526106583,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:00:00Z","timestamp":1774483200000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-026-07892-7","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:55:51Z","timestamp":1771520151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics and risk factors of antipsychotic-associated metabolic syndrome in bipolar disorder: a retrospective analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Yang","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yichun","family":"Deng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"issue":"26","key":"7892_CR1","doi-asserted-by":"publisher","first-page":"e42803","DOI":"10.1097\/md.0000000000042803","volume":"104","author":"X Wang","year":"2025","unstructured":"Wang X, Ye F, Zhang Z, Zhang Q, Li G. Effects of olanzapine combined with sodium valproate on symptoms, inflammatory markers, and cognitive function in patients with bipolar disorder. Medicine. 2025;104(26):e42803. https:\/\/doi.org\/10.1097\/md.0000000000042803.","journal-title":"Medicine"},{"issue":"1","key":"7892_CR2","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1002\/hbm.25098","volume":"43","author":"CRK Ching","year":"2022","unstructured":"Ching CRK, Hibar DP, Gurholt TP, Nunes A, Thomopoulos SI, Ab\u00e9 C, et al. What we learn about bipolar disorder from large-scale neuroimaging: findings and future directions from the ENIGMA bipolar disorder working group. Hum Brain Mapp. 2022;43(1):56\u201382. https:\/\/doi.org\/10.1002\/hbm.25098.","journal-title":"Hum Brain Mapp"},{"key":"7892_CR3","doi-asserted-by":"publisher","unstructured":"Gkintoni E, Skokou M, Gourzis P. Integrating clinical neuropsychology and psychotic spectrum disorders: a systematic analysis of cognitive dynamics, interventions, and underlying mechanisms. Medicine (Kaunas). 2024;60(4). https:\/\/doi.org\/10.3390\/medicina60040645.","DOI":"10.3390\/medicina60040645"},{"issue":"12","key":"7892_CR4","doi-asserted-by":"publisher","first-page":"e71139","DOI":"10.1002\/brb3.71139","volume":"15","author":"P Yao","year":"2025","unstructured":"Yao P, Ni P, Yin L. Efficacy of different combination therapies for mania in bipolar disorder: A systematic review and Meta-Analysis. Brain Behav. 2025;15(12):e71139. https:\/\/doi.org\/10.1002\/brb3.71139.","journal-title":"Brain Behav"},{"issue":"1","key":"7892_CR5","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s40261-019-00860-y","volume":"40","author":"L Sun","year":"2020","unstructured":"Sun L, Yagoda S, Yao B, Graham C, von Moltke L. Combination of olanzapine and Samidorphan has no clinically significant effect on the pharmacokinetics of lithium or valproate. Clin Drug Investig. 2020;40(1):55\u201364. https:\/\/doi.org\/10.1007\/s40261-019-00860-y.","journal-title":"Clin Drug Investig"},{"issue":"8","key":"7892_CR6","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1111\/bdi.13135","volume":"23","author":"LN Yatham","year":"2021","unstructured":"Yatham LN, Chakrabarty T, Bond DJ, Schaffer A, Beaulieu S, Parikh SV, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) recommendations for the management of patients with bipolar disorder with mixed presentations. Bipolar Disord. 2021;23(8):767\u201388. https:\/\/doi.org\/10.1111\/bdi.13135.","journal-title":"Bipolar Disord"},{"issue":"3","key":"7892_CR7","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1007\/s11096-025-01919-x","volume":"47","author":"I Fitzgerald","year":"2025","unstructured":"Fitzgerald I, Bayraktar I, Eiden B, Gittins R, Magni E, Humbert-Claude M, et al. Comparative efficacy and safety of alternatives to sodium valproate in the management of bipolar affective disorder in people of child-bearing age: a narrative review by the European society of clinical pharmacy\u2019s mental health specialist interest group. Int J Clin Pharm. 2025;47(3):666\u201375. https:\/\/doi.org\/10.1007\/s11096-025-01919-x.","journal-title":"Int J Clin Pharm"},{"key":"7892_CR8","unstructured":"Keck PE Jr., McElroy SL. Carbamazepine and valproate in the maintenance treatment of bipolar disorder. J Clin Psychiatry. 2002;63(Suppl 10):13\u2009\u2013\u20097."},{"issue":"1","key":"7892_CR9","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1001\/archpsyc.59.1.62","volume":"59","author":"M Tohen","year":"2002","unstructured":"Tohen M, Chengappa KN, Suppes T, Zarate CA Jr., Calabrese JR, Bowden CL, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59(1):62\u20139. https:\/\/doi.org\/10.1001\/archpsyc.59.1.62.","journal-title":"Arch Gen Psychiatry"},{"issue":"8","key":"7892_CR10","doi-asserted-by":"publisher","first-page":"3691","DOI":"10.1007\/s12325-025-03211-w","volume":"42","author":"AJ Cutler","year":"2025","unstructured":"Cutler AJ, Panchmatia HR, Hughes AG, Webb NS, Doane MJ, Jain R. Healthcare resource utilization 6 months before and after Olanzapine\/Samidorphan initiation: Real-World assessment of patients with schizophrenia or bipolar I disorder. Adv Therapy. 2025;42(8):3691\u2013707. https:\/\/doi.org\/10.1007\/s12325-025-03211-w.","journal-title":"Adv Therapy"},{"issue":"3","key":"7892_CR11","doi-asserted-by":"publisher","first-page":"34224","DOI":"10.52965\/001c.34224","volume":"10","author":"HW Haddad","year":"2022","unstructured":"Haddad HW, Boardman E, Williams B, Mouhaffel R, Kaye AM, Kaye AD. Combination olanzapine and Samidorphan for the management of schizophrenia and bipolar 1 disorder in adults: A narrative review. Health Psychol Res. 2022;10(3):34224. https:\/\/doi.org\/10.52965\/001c.34224.","journal-title":"Health Psychol Res"},{"key":"7892_CR12","doi-asserted-by":"publisher","unstructured":"Rehan ST, Siddiqui AH, Khan Z, Imran L, Syed AA, Tahir MJ et al. Samidorphan\/olanzapine combination therapy for schizophrenia: efficacy, tolerance and adverse outcomes of regimen, evidence-based review of clinical trials. Ann Med Surg (Lond). 2022;79:104115. https:\/\/doi.org\/10.1016\/j.amsu.2022.104115.","DOI":"10.1016\/j.amsu.2022.104115"},{"key":"7892_CR13","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. editor: American Psychiatric Association. Diagnostic and statistical METSnual of MentalDisorders \/DSM-5).5th; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"key":"7892_CR14","doi-asserted-by":"publisher","unstructured":"Correll CU, Doane MJ, McDonnell D, Akerman S, Saklad SR. Olanzapine\/samidorphan effects on weight gain: an individual patient data meta-analysis of phase 2 and 3 randomized double-blind studies. J Clin Psychiatry. 2025;86(1). https:\/\/doi.org\/10.4088\/JCP.24m15526.","DOI":"10.4088\/JCP.24m15526"},{"issue":"14","key":"7892_CR15","doi-asserted-by":"publisher","first-page":"e21323","DOI":"10.1097\/MD.0000000000021323","volume":"100","author":"Z Xing","year":"2021","unstructured":"Xing Z, Qiu Y, Fei Y, Xia B, Abuduwaili M, Zhu J, et al. Protective strategy of parathyroid glands during thyroid lobectomy: A retrospective cohort and case-control study. Med (Baltim). 2021;100(14):e21323. https:\/\/doi.org\/10.1097\/MD.0000000000021323.","journal-title":"Med (Baltim)"},{"issue":"1","key":"7892_CR16","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1056\/NEJMra1906193","volume":"383","author":"AF Carvalho","year":"2020","unstructured":"Carvalho AF, Firth J, Vieta E, Bipolar Disorder. N Engl J Med. 2020;383(1):58\u201366. https:\/\/doi.org\/10.1056\/NEJMra1906193.","journal-title":"N Engl J Med"},{"key":"7892_CR17","doi-asserted-by":"publisher","unstructured":"Fusar-Poli L, Amerio A, Cimpoesu P, Natale A, Salvi V, Zappa G, et al. Lipid and glycemic profiles in patients with bipolar disorder: cholesterol levels are reduced in mania. Medicine (Kaunas). 2020;57(1). https:\/\/doi.org\/10.3390\/medicina57010028.","DOI":"10.3390\/medicina57010028"},{"issue":"9896","key":"7892_CR18","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/s0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet (London England). 2013;382(9896):951\u201362. https:\/\/doi.org\/10.1016\/s0140-6736(13)60733-3.","journal-title":"Lancet (London England)"},{"key":"7892_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2147\/ndt.S81146","volume":"11","author":"L Xu","year":"2015","unstructured":"Xu L, Lu Y, Yang Y, Zheng Y, Chen F, Lin Z. Olanzapine-valproate combination versus olanzapine or valproate monotherapy in the treatment of bipolar I mania: a randomized controlled study in a Chinese population group. Neuropsychiatr Dis Treat. 2015;11:1265\u201371. https:\/\/doi.org\/10.2147\/ndt.S81146.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"4","key":"7892_CR20","doi-asserted-by":"publisher","first-page":"e70061","DOI":"10.1002\/npr2.70061","volume":"45","author":"A Butt","year":"2025","unstructured":"Butt A, Sadiq S. Does adjuvant Metformin reduce Olanzapine-Induced metabolic adverse effects in patients diagnosed with schizophrenia. Neuropsychopharmacol Rep. 2025;45(4):e70061. https:\/\/doi.org\/10.1002\/npr2.70061.","journal-title":"Neuropsychopharmacol Rep"},{"issue":"1","key":"7892_CR21","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1017\/s1092852925100400","volume":"30","author":"L Citrome","year":"2025","unstructured":"Citrome L. Choosing among the long-acting injectable antipsychotics: an evidence-based pragmatic guide. CNS Spectr. 2025;30(1):e73. https:\/\/doi.org\/10.1017\/s1092852925100400.","journal-title":"CNS Spectr"},{"issue":"1","key":"7892_CR22","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/JCP.0b013e31819302c3","volume":"29","author":"A Gunes","year":"2009","unstructured":"Gunes A, Melkersson KI, Scordo MG, Dahl ML. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine. J Clin Psychopharmacol. 2009;29(1):65\u20138. https:\/\/doi.org\/10.1097\/JCP.0b013e31819302c3.","journal-title":"J Clin Psychopharmacol"},{"issue":"4","key":"7892_CR23","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3109\/13651501.2014.957705","volume":"18","author":"X Ma","year":"2014","unstructured":"Ma X, Maimaitirexiati T, Zhang R, Gui X, Zhang W, Xu G, et al. HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. Int J Psychiatry Clin Pract. 2014;18(4):229\u201342. https:\/\/doi.org\/10.3109\/13651501.2014.957705.","journal-title":"Int J Psychiatry Clin Pract"},{"issue":"5","key":"7892_CR24","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1128\/iai.4.5.632-641.1971","volume":"4","author":"JJ Crawford","year":"1971","unstructured":"Crawford JJ. Interaction of actinomyces organisms with cationic polypeptides. I. Histochemical studies of infected human and animal tissues. Infect Immun. 1971;4(5):632\u201341. https:\/\/doi.org\/10.1128\/iai.4.5.632-641.1971.","journal-title":"Infect Immun"},{"key":"7892_CR25","doi-asserted-by":"publisher","DOI":"10.2147\/NDT.S313840","author":"L Citrome","year":"2021","unstructured":"Citrome L, Graham C, Simmons A, Jiang Y, Todtenkopf MS, Silverman B, et al. An Evidence-Based review of OLZ\/SAM for treatment of adults with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat. 2021. https:\/\/doi.org\/10.2147\/NDT.S313840. 17(2885\u2009\u2013\u2009904.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"10","key":"7892_CR26","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1177\/0269881119856850","volume":"33","author":"JI Cunningham","year":"2019","unstructured":"Cunningham JI, Eyerman DJ, Todtenkopf MS, Dean RL, Deaver DR, Sanchez C, et al. Samidorphan mitigates olanzapine-induced weight gain and metabolic dysfunction in rats and non-human primates. J Psychopharmacol. 2019;33(10):1303\u201316. https:\/\/doi.org\/10.1177\/0269881119856850.","journal-title":"J Psychopharmacol"},{"key":"7892_CR27","doi-asserted-by":"publisher","unstructured":"Silverman BL, Martin W, Memisoglu A, DiPetrillo L, Correll CU, Kane JM. A randomized, double-blind, placebo-controlled proof of concept study to evaluate samidorphan in the prevention of olanzapine-induced weight gain in healthy volunteers. Schizophr Res. 2018;195:245\u2009\u2013\u200951. https:\/\/doi.org\/10.1016\/j.schres.2017.10.014.","DOI":"10.1016\/j.schres.2017.10.014"},{"issue":"6","key":"7892_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","volume":"176","author":"WF Martin","year":"2019","unstructured":"Martin WF, Correll CU, Weiden PJ, Jiang Y, Pathak S, DiPetrillo L, et al. Mitigation of Olanzapine-Induced weight gain with Samidorphan, an opioid antagonist: A randomized Double-Blind phase 2 study in patients with schizophrenia. Am J Psychiatry. 2019;176(6):457\u201367. https:\/\/doi.org\/10.1176\/appi.ajp.2018.18030280.","journal-title":"Am J Psychiatry"},{"issue":"1","key":"7892_CR29","doi-asserted-by":"publisher","first-page":"40266","DOI":"10.1038\/s41598-025-24094-5","volume":"15","author":"X Tian","year":"2025","unstructured":"Tian X, Qu Z, Yang X, Cao Y, Zhang B. Synergistic effects of body fat percentage and C-reactive protein triglyceride-glucose index on cardiovascular disease risk: a Chinese cohort study. Sci Rep. 2025;15(1):40266. https:\/\/doi.org\/10.1038\/s41598-025-24094-5.","journal-title":"Sci Rep"},{"issue":"12","key":"7892_CR30","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.kjms.2017.07.005","volume":"33","author":"PH Chen","year":"2017","unstructured":"Chen PH, Lin YK, Chang CK, Chiang SJ, Tsai SY. Dysregulation of glucose metabolism since young adulthood increases the risk of cardiovascular diseases in patients with bipolar disorder. Kaohsiung J Med Sci. 2017;33(12):630\u20136. https:\/\/doi.org\/10.1016\/j.kjms.2017.07.005.","journal-title":"Kaohsiung J Med Sci"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-026-07892-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-026-07892-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T10:52:18Z","timestamp":1774522338000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12888-026-07892-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7892"],"URL":"https:\/\/doi.org\/10.1186\/s12888-026-07892-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"15 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was reviewed and approved by the Ethics Committee of West China Hospital, Sichuan University (Institutional Review Board). Due to the retrospective nature of the study and the use of anonymized clinical data, the requirement for informed consent was waived by the Ethics Committee in accordance with national regulations. All procedures were conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"258"}}